

Amendment dated February 13, 2012

After Final Office Action of September 13, 2011

AMENDMENTS TO THE CLAIMS

1. (Previously presented) A method for assembling a modulatable fusion molecule polypeptide, comprising:

generating a circular permutation of an insertion nucleic acid sequence, wherein the insertion nucleic acid sequence encodes a polypeptide that recognizes an input signal; and

inserting the insertion sequence into an acceptor nucleic acid sequence, wherein the acceptor sequence encodes a polypeptide that produces an output signal provided the output signal is not fluorescence, wherein the fused insertion and acceptor sequences encode a modulatable fusion polypeptide having the output signal functionally coupled to the input signal.

2. (Original) The method according to claim 1, wherein the insertion sequence is inserted at a selected site in the acceptor sequence.

3. (Original) The method according to claim 1, wherein the insertion sequence is inserted at a random site in the acceptor sequence.

4. (Previously presented) A method for assembling a modulatable fusion molecule polypeptide, comprising:

generating a circular permutation of an insertion nucleic acid sequence, wherein the insertion nucleic acid sequence encodes a polypeptide that produces an output signal provided the output signal is not fluorescence; and

inserting the insertion sequence into an acceptor nucleic acid sequence, wherein the acceptor sequence encodes a polypeptide that recognizes an input signal, wherein the fused insertion and acceptor sequences encode a modulatable fusion polypeptide having the output signal functionally coupled to the input signal.

5. (Original) The method according to claim 4, wherein the insertion sequence is inserted at a selected site in the acceptor sequence.

Amendment dated February 13, 2012

After Final Office Action of September 13, 2011

6. (Original) The method according to claim 4, wherein the insertion sequence is inserted at a random site in the acceptor sequence.

7. (Previously presented) A method for assembling a modulatable fusion molecule polypeptide, comprising:

generating a circular permutation of an acceptor nucleic acid sequence, wherein the acceptor nucleic acid sequence encodes a polypeptide that recognizes an input signal; and

inserting the insertion sequence into an acceptor nucleic acid sequence, wherein the insertion sequence encodes a polypeptide that produces an output signal provided the output signal is not fluorescence, wherein the fused insertion and acceptor sequences encode a modulatable fusion polypeptide having the output signal functionally coupled to the input signal.

8. (Previously presented) The method according to claim 7, wherein the insertion sequence is inserted at a selected site in the acceptor sequence.

9. (Previously presented) The method according to claim 7, wherein the insertion sequence is inserted at a random site in the acceptor sequence.

10. (Previously presented) A method of assembling a modulatable fusion molecule polypeptide, comprising:

generating a circular permutation of an acceptor nucleic acid sequence, wherein the acceptor nucleic acid sequence encodes a polypeptide that produces an output signal provided the output signal is not fluorescence; and

inserting the insertion sequence into an acceptor nucleic acid sequence, wherein the insertion sequence encodes a polypeptide that recognizes an input signal, wherein the fused insertion and acceptor sequences encode a modulatable fusion polypeptide having the output signal functionally coupled to the input signal.

Amendment dated February 13, 2012

After Final Office Action of September 13, 2011

11. (Previously presented) The method according to claim 10, wherein the insertion sequence is inserted at a selected site in the acceptor sequence.

12. (Previously presented) The method according to claim 10, wherein the insertion sequence is inserted at a random site in the acceptor sequence.

13-15. (Cancelled)

16. (Withdrawn) A method for modulating a cellular activity, comprising:

providing a fusion molecule generated according to the method of claim 1 to a cell, wherein a change in state of at least the insertion sequence or the acceptor sequence modulates a cellular activity, and wherein the change in state which modulates the cellular activity is coupled to a change in state of the respective other portion of the fusion molecule; and

changing the state of the respective other portion of the fusion molecule, thereby modulating the cellular activity.

17. (Withdrawn) A method for delivering a bio-effective molecule to a cell, comprising:

providing a fusion molecule associated with a bio-effective molecule generated according to the method of claim 1 to the cell, the fusion molecule comprising an insertion sequence and an acceptor sequence, wherein either the insertion sequence or the acceptor sequence binds to a cellular marker of a pathological condition and wherein upon binding to the marker, the fusion molecule dissociates from the bio-effective molecule, thereby delivering the molecule to the cell.

18. (Withdrawn) A method for delivering a bio-effective molecule intracellularly, comprising:

providing a fusion molecule associated with a bio-effective molecule generated according to the method of claim 1 to the cell, the fusion molecule comprising an insertion sequence and an acceptor sequence,

wherein either the insertion sequence or acceptor sequence comprises a transport sequence for transporting the fusion molecule intracellularly, and

wherein release of the bio-effective molecule from the fusion molecule is coupled to transport of the fusion molecule intracellularly.

19. (Withdrawn) The method according to claim 18, wherein either the insertion sequence or the acceptor sequence is capable of binding to a biomolecule, and wherein binding of the fusion molecule with the biomolecule localizes the fusion molecule comprising the bio-effective molecule intracellularly and disassociates the bio-effective molecule from the fusion molecule.

20. (Withdrawn) A method for modulating a molecular pathway in a cell, comprising:
providing a fusion molecule generated according to the method of claim 1 to the cell, the fusion molecule comprising an insertion sequence and an acceptor sequence,

wherein the activity of the insertion sequence and acceptor sequence are coupled, and responsive to a signal, and

wherein the activity of either the insertion sequence or the acceptor sequence modulates the activity or expression of a molecular pathway molecule in the cell; and exposing the fusion molecule to the signal.

21. (Withdrawn) A method for controlling the activity of a nucleic acid regulatory sequence, comprising:

providing a fusion molecule generated according to the method of claim 1, the fusion molecule comprising an insertion sequence and an acceptor sequence,

wherein either the insertion sequence or the acceptor sequence responds to a signal, and

wherein the respective other sequence of the fusion molecule binds to the nucleic acid regulatory sequence when the signal is responded to; and

exposing the fusion molecule to the signal.

22. (Withdrawn) A sensor molecule for detecting a target analyte, comprising:
an insertion sequence and an acceptor sequence, generated according to the method of claim 1,

Amendment dated February 13, 2012

After Final Office Action of September 13, 2011

wherein either the insertion sequence "pr" the acceptor sequence binds the analyte, and wherein binding of the analyte is coupled to production of a signal from the sensor molecule.

23. (Withdrawn) A fusion molecule, comprising:

an insertion sequence and an acceptor sequence, generated according to the method of any of claim 1,

wherein either the insertion sequence or the acceptor sequence transports the fusion molecule intracellularly and wherein intracellular transport of the fusion molecule is coupled to binding of the fusion molecule to a bio-effective molecule.

24. (Withdrawn) A fusion molecule, comprising:

an insertion sequence and an acceptor sequence generated according to the method of claim 1, wherein either the insertion sequence or the acceptor sequence binds to a nucleic acid molecule, and wherein nucleic acid binding activity is coupled to the response of the respective other sequence of the fusion molecule to a signal.

25. (Withdrawn) A fusion molecule, comprising:

an insertion sequence and an acceptor sequence generated according to the method of claim 1,

wherein either the insertion sequence or the acceptor sequence associates with a bio-effective molecule, and disassociates from the bio-effective molecule, when the respective other sequence of the fusion molecule binds to a cellular marker of a pathological condition.

26. (Withdrawn) A fusion molecule capable of switching from a non-toxic to a toxic state, comprising:

an insertion sequence and an acceptor sequence generated according to the method of claim 1,

wherein either the insertion sequence or the acceptor sequence binds to a cellular marker of a pathology, and

Amendment dated February 13, 2012

After Final Office Action of September 13, 2011

wherein binding of the marker to the fusion protein switches the fusion protein from a non-toxic state to a toxic state.

27. (Withdrawn) A fusion molecule capable of switching from a toxic state to a less toxic state, comprising:

an insertion sequence and an acceptor sequence generated according to the method of claim 1, wherein either the insertion sequence or acceptor sequence binds to a cellular marker of a healthy cell, and

wherein binding of the marker to the fusion protein switches the fusion protein from a toxic state to a less toxic state.

28. (Withdrawn) A molecular switch for controlling a cellular pathway, comprising:

a fusion molecule comprising an insertion sequence and an acceptor sequence generated according to the method of claim 1,

wherein the states of the insertion and acceptor sequences are coupled, and responsive to a signal, and

wherein the state of either the insertion sequence or the acceptor sequence modulates the activity or expression of a molecular pathway molecule in a cell.

29. (Withdrawn) A modified molecular switch generated according to the method of claim 1, wherein said molecular switch is responsive to at least one ligand that differs from a ligand recognized by the unmodified form of said switch.

30. (Withdrawn) A library, comprising a plurality of library members,

wherein each library member comprises a first nucleic acid sequence encoding a first polypeptide having a first state, the first nucleic acid sequence having been circularly permuted and inserted into a second nucleic acid sequence encoding a second polypeptide having a second state.

Amendment dated February 13, 2012

After Final Office Action of September 13, 2011

31. (Withdrawn) A library comprising a plurality of library members comprising fusion molecules generated according to claim 1.
32. (Withdrawn) A library generated according to claim 31, wherein said library is generated by iterative processing of at least one library generated according to claim 1.
33. (Withdrawn) A library according to claim 32, generated by inserting a selected circularly permuted insert sequence generated from a first library into an acceptor sequence, to generate a second library having a plurality of members each comprising said selected circularly permuted insert sequence.
34. (Withdrawn) A library according to claim 33, wherein said selected circularly permuted insert sequence is inserted at a random site in the acceptor sequence.
35. (Withdrawn) A library according to claim 33, wherein said selected circularly permuted insert sequence is inserted at a non-random site in the acceptor sequence.
36. (Withdrawn) An isolated nucleic acid encoding a molecular switch protein comprising a nucleotide sequence selected from any of SEQ ID NOS: 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 56, 58, 60, 62, 64, 66, 68, 70, 72, and 74, or an effective fragment thereof.
37. (Withdrawn) A molecular switch protein comprising an amino acid sequence selected from any of SEQ ID NOS: 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, and 75, or an effective fragment thereof.
- 38-49. (Cancelled)